A patient expecting one drug would have received another without knowing it.
Em maio de 2026, a Anvisa ordenou o recolhimento preventivo de lotes de dois medicamentos para colesterol — atorvastatina e rosuvastatina, fabricados pela Cimed — após a descoberta de que cápsulas de um remédio foram embaladas nas caixas do outro. O erro, identificado pela própria empresa durante o controle de qualidade, revela como uma falha pontual numa linha de produção pode romper silenciosamente o fio de confiança entre paciente e tratamento. Para milhões de brasileiros que dependem dessas estatinas como escudo diário contra infartos e derrames, a troca inadvertida de medicamentos não é apenas uma irregularidade técnica — é uma interrupção invisível no cuidado com a própria vida.
- Caixas de atorvastatina 40 mg continham, na verdade, cartuchos de rosuvastatina 20 mg — dois medicamentos distintos, com dosagens e composições diferentes, trocados sem que o paciente soubesse.
- A falha viola diretamente a RDC 658/2022, que regula as boas práticas de fabricação farmacêutica, e levou a Anvisa a suspender imediatamente a venda, distribuição e uso do lote 2424299.
- Pacientes que tomaram o medicamento errado podem ter ficado com o colesterol mal controlado ou, no sentido inverso, expostos a riscos como dores musculares e complicações hepáticas associadas a doses inadequadas.
- A própria Cimed identificou o problema e iniciou o recall voluntário — um sinal de que o sistema de vigilância funcionou, ainda que a falha já pudesse ter chegado às mãos de consumidores.
- Quem adquiriu qualquer um dos dois medicamentos do lote afetado deve verificar a embalagem e consultar um profissional de saúde para avaliar se recebeu o tratamento correto.
A Anvisa determinou, em 14 de maio de 2026, o recolhimento do lote 2424299 de atorvastatina cálcica 40 mg e rosuvastatina cálcica 20 mg, ambos fabricados pela Cimed. O motivo: cartuchos de rosuvastatina foram colocados dentro das caixas rotuladas como atorvastatina. Embora pertençam à mesma classe farmacológica, as duas estatinas têm composições e dosagens distintas — e um paciente que esperava um medicamento recebeu outro sem saber.
A empresa identificou o erro internamente e iniciou o recall de forma voluntária. A Anvisa confirmou a irregularidade, enquadrou a falha como violação às normas de boas práticas de fabricação e ordenou a retirada imediata do lote de farmácias, depósitos e residências.
Estatinas estão entre os medicamentos mais prescritos no Brasil. Elas reduzem o LDL, elevam o HDL e diminuem triglicerídeos — uma rotina diária para milhões de pessoas que buscam prevenir infartos e derrames. Quando essa rotina é silenciosamente interrompida por uma troca de medicamento, o risco cardiovascular pode aumentar sem que o paciente perceba. O cenário inverso — receber uma dose mais alta do que a prescrita — também traz riscos, como dores musculares e sobrecarga hepática.
O recall se restringe a um único número de lote, o que limita o alcance do problema. Ainda assim, a Anvisa não divulgou quantas unidades foram distribuídas nem quantos pacientes podem ter sido afetados antes da intervenção. A recomendação é clara: quem utilizou qualquer um dos dois medicamentos deve verificar a embalagem e conversar com seu médico ou farmacêutico.
Brazil's health regulator Anvisa moved to pull specific batches of two common cholesterol medications from shelves this month after discovering a packaging error that could have left patients taking the wrong drug. The agency published the recall order on May 14, 2026, in the official government gazette, targeting batch 2424299 of both atorvastatina cálcica 40 mg and rosuvastatina cálcica 20 mg, both manufactured by the pharmaceutical company Cimed.
The problem was straightforward but serious: cartridges of rosuvastatina 20 mg had been placed inside boxes labeled as atorvastatina 40 mg. While both medications belong to the same class of drugs used to manage cholesterol, they are distinct formulations with different dosages and chemical compositions. A patient expecting one drug would have received another without knowing it. The manufacturer itself flagged the mix-up and initiated the voluntary recall after quality control staff caught the error.
Statins like these two medications are among the most widely prescribed drugs in Brazil and globally. They work by lowering LDL cholesterol—the harmful kind that builds up in arteries—while raising HDL, the protective form. They also help reduce triglycerides, another risk factor for heart disease. For millions of Brazilians managing high cholesterol, these drugs are part of a daily routine meant to prevent heart attacks and strokes. When a patient takes the wrong statin without realizing it, the protective effect breaks down. They may be underdosed, overdosed, or receiving a formulation their body responds to differently.
Anvisa determined that the packaging failure violated article 4 of regulation RDC 658/2022, which sets standards for good manufacturing practices and quality control in pharmaceutical production. The violation was serious enough to warrant not just a recall but a full suspension of sales, distribution, and use of the affected batch. The agency ordered that all units of batch 2424299 be removed from pharmacies, warehouses, and patients' medicine cabinets.
The recall affects only one batch number, which limits the scope of potential exposure. Still, patients who filled prescriptions for either medication during the window when this batch was in circulation should check their packaging. The visible difference between the two drugs—different labels, different box designs—should make the error detectable to anyone who looks closely. But many people don't examine their medication packaging carefully, especially if they've been taking the same drug for months or years and simply refill it out of habit.
For those who received the wrong medication, the consequences depend on how long they took it and what their individual health profile looks like. Someone who needed atorvastatina 40 mg but received rosuvastatina 20 mg instead may have had inadequate cholesterol control during that period, potentially increasing their cardiovascular risk. The reverse scenario—receiving a higher dose than prescribed—carries its own risks, including muscle pain and liver complications that can accompany statin use at higher levels.
Anvisa's action reflects a system working as it should: a manufacturer catching its own mistake, reporting it, and regulators responding swiftly to protect public health. But it also underscores how fragile the chain of custody can be, even in a regulated industry. A single error in a packaging line, undetected until it reaches the distribution system, can affect thousands of people. The agency has not disclosed how many units were affected or how many patients may have received the wrong medication before the recall was issued.
Citações Notáveis
The packaging failure violated article 4 of regulation RDC 658/2022, which sets standards for good manufacturing practices and quality control in pharmaceutical production.— Anvisa
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that rosuvastatina ended up in atorvastatina boxes? Aren't they basically the same thing?
They're both statins, yes, but they're different drugs with different dosages. If you're supposed to take atorvastatina 40 and you get rosuvastatina 20 instead, your cholesterol isn't being controlled the way your doctor intended. Over weeks or months, that gap in protection adds up.
So someone could have had a heart attack because of this?
Potentially, yes. If someone's cardiovascular risk was being managed by that specific dose of that specific drug, and they unknowingly switched to a lower dose of a different one, their protection weakened. We don't know how long people were taking the wrong medication before the recall.
How did Cimed catch this?
Quality control staff spotted the mix-up during their own checks. The company reported it themselves, which is actually the system working. But it means the error made it past initial packaging checks—someone put the wrong cartridges in the wrong boxes, and it wasn't caught until later.
What should patients do now?
Check the batch number on their medication bottle. If it's 2424299, they should contact their pharmacy and doctor immediately. They need to verify they actually got what was prescribed and discuss whether they need to restart or adjust their treatment.
Is this a sign of bigger problems at Cimed?
One batch error doesn't necessarily mean systemic failure, but it does show that even in regulated manufacturing, mistakes slip through. Anvisa will likely investigate whether this was an isolated incident or part of a pattern.